haemophilia A

News

BioMarin’s haemophilia A gene therapy gets US approval

The FDA has approved BioMarin Pharma’s Roctavian as the first gene therapy for haemophilia A, giving patients an alternative to regular injections of blood clotting factor

News

Pfizer says haemophilia drug works, but safety will be key

Pfizer has reported that its anti-tissue factor pathway inhibitor marstacimab is effective at reducing bleed rates in patients with haemophilia A and B, working as well as

News

Sanofi gets FDA nod for long-acting haemophilia A drug

Once-weekly Altuviiio could be potential $2 billion-plus blockbuster, according to analysts.

News

BioMarin gets first access deal in EU for gene therapy Rocta...

BioMarin's has signed the first contract with an insurer in Germany for Roctavian, its recently approved gene therapy for haemophilia A, as it tests out its outcomes-based agreement (OBA) r

News

Pfizer, Sangamo resume haemophilia gene therapy trial

Pfizer and Sangamo have restarted recruitment of patients into their registration trial for haemophilia A gene therapy giroctocogene fitelparvovec, after the FDA lifted a clinical hold on t

News

Roctavian okay sets up another gene therapy test for Europe

BioMarin Pharma has its landmark first approval for Roctavian – the first for a haemophilia gene therapy – and will now have to see if that can convert that into a viable business in Europe

BioMarin’s haemophilia A gene therapy gets US approval

Pfizer says haemophilia drug works, but safety will be key

Sanofi gets FDA nod for long-acting haemophilia A drug

BioMarin gets first access deal in EU for gene therapy Rocta...

Pfizer, Sangamo resume haemophilia gene therapy trial

Roctavian okay sets up another gene therapy test for Europe

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

haemophilia A

Editor's Picks